Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

1.839 +0.149 (+8.83%)
Streaming Delayed Price Updated: 2:04 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 861,572
Open 1.670
Bid (Size) 1.830 (2,500)
Ask (Size) 1.840 (1,500)
Prev. Close 1.690
Today's Range 1.640 - 1.845
52wk Range 0.7911 - 3.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
Which stocks are moving after the closing bell on Tuesday? ↗
Via Chartmill

Performance

YTD
+10.8%
+10.8%
1 Month
+13.5%
+13.5%
3 Month
-13.2%
-13.2%
6 Month
+12.5%
+12.5%
1 Year
+105.4%
+105.4%

More News

Read More
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
News headline image
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Thursday's session ↗
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
From Neumora Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Neumora Therapeutics, Inc. - Common Stock publicly traded?
Yes, Neumora Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Neumora Therapeutics, Inc. - Common Stock trade on?
Neumora Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neumora Therapeutics, Inc. - Common Stock?
The ticker symbol for Neumora Therapeutics, Inc. - Common Stock is NMRA on the Nasdaq Stock Market
What is the current price of Neumora Therapeutics, Inc. - Common Stock?
The current price of Neumora Therapeutics, Inc. - Common Stock is 1.839
When was Neumora Therapeutics, Inc. - Common Stock last traded?
The last trade of Neumora Therapeutics, Inc. - Common Stock was at 07/07/26 02:04 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.